In patients who undergo a short pause in the anti-retroviral therapy (ART), regular dose of an Antibody, which prevents HIV from binding on the human immune cells, has shown to suppress HIV levels for up to 4 months.
The antibody known as UB-421 showed these results in a phase 2 clinical trial and encouragingly did not induce antibody resistant HIV.
These results are also encouraging since previously tried antibodies which target proteins on the Virus directly increase the mutation rate in the virus inducing resistance to the treatment.
Read the full story: NIAID (via ScienceDaily)
Scientific publication: NEJM